AU2024281601A1 - Anti-synaptotagmin 2 antibody - Google Patents

Anti-synaptotagmin 2 antibody

Info

Publication number
AU2024281601A1
AU2024281601A1 AU2024281601A AU2024281601A AU2024281601A1 AU 2024281601 A1 AU2024281601 A1 AU 2024281601A1 AU 2024281601 A AU2024281601 A AU 2024281601A AU 2024281601 A AU2024281601 A AU 2024281601A AU 2024281601 A1 AU2024281601 A1 AU 2024281601A1
Authority
AU
Australia
Prior art keywords
antibody
present
amino acid
motor neuron
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024281601A
Other languages
English (en)
Inventor
Norihiro YUMOTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiksak Bioengineering Inc
Original Assignee
Jiksak Bioengineering Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiksak Bioengineering Inc filed Critical Jiksak Bioengineering Inc
Publication of AU2024281601A1 publication Critical patent/AU2024281601A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
AU2024281601A 2023-05-31 2024-05-30 Anti-synaptotagmin 2 antibody Pending AU2024281601A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2023-089889 2023-05-31
JP2023089889 2023-05-31
JP2023-180242 2023-10-19
JP2023180242 2023-10-19
PCT/JP2024/019802 WO2024248062A1 (ja) 2023-05-31 2024-05-30 抗シナプトタグミン2抗体

Publications (1)

Publication Number Publication Date
AU2024281601A1 true AU2024281601A1 (en) 2026-01-08

Family

ID=93658014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024281601A Pending AU2024281601A1 (en) 2023-05-31 2024-05-30 Anti-synaptotagmin 2 antibody

Country Status (4)

Country Link
EP (1) EP4722241A1 (https=)
JP (1) JPWO2024248062A1 (https=)
AU (1) AU2024281601A1 (https=)
WO (1) WO2024248062A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
JP2008143867A (ja) 2006-12-12 2008-06-26 Institute Of Physical & Chemical Research シナプス形成促進剤
JP2012092048A (ja) 2010-10-27 2012-05-17 Keio Gijuku 軽度認知障害の治療用医薬剤、初期認知症の治療用医薬剤、神経細胞の樹状突起形成促進剤、神経細胞のシナプス形成促進剤、検定方法およびスクリーニング方法
JP7323874B2 (ja) 2019-03-27 2023-08-09 国立大学法人東北大学 神経軸索分岐異常の改善剤
JP7849713B2 (ja) 2019-07-05 2026-04-22 株式会社Jiksak Bioengineering 神経細胞のシナプス形成誘導方法および該方法に用いるマイクロビーズ
JP2022053535A (ja) 2020-09-24 2022-04-05 株式会社Jiksak Bioengineering シナプス形成を促進するための組成物
JP2023028848A (ja) 2021-08-20 2023-03-03 株式会社Jiksak Bioengineering シナプス形成促進剤
JP2023089889A (ja) 2021-12-16 2023-06-28 株式会社ピカソ美化学研究所 皮膚用乳化組成物
WO2023210585A1 (ja) 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤
DE102022205824A1 (de) 2022-06-08 2023-12-14 Robert Bosch Gesellschaft mit beschränkter Haftung Verfahren und Vorrichtung zum Trainieren eines neuronalen Netzes

Also Published As

Publication number Publication date
WO2024248062A1 (ja) 2024-12-05
EP4722241A1 (en) 2026-04-08
JPWO2024248062A1 (https=) 2024-12-05

Similar Documents

Publication Publication Date Title
US20250277028A1 (en) Targeting agent
CN104781278B (zh) 针对tau的抗体
JP6673608B2 (ja) ニューロン再生療法に適するナノボディー
Jiang et al. Single-domain antibody-based protein degrader for synucleinopathies
González et al. Frizzled 1 and Wnt1 as new potential therapeutic targets in the traumatically injured spinal cord
WO2021006075A1 (ja) 神経細胞のシナプス形成誘導方法および該方法に用いるマイクロビーズ
Conroy et al. Postsynaptic neuroligin enhances presynaptic inputs at neuronal nicotinic synapses
AU2024281601A1 (en) Anti-synaptotagmin 2 antibody
AU2024283291A1 (en) Anti-synaptotagmin 2 antibody
WO2025084396A1 (ja) 抗シナプトタグミン2抗体
WO2025084393A1 (ja) 抗シナプトタグミン2抗体
WO2025084394A1 (ja) 抗シナプトタグミン2抗体
WO2025084397A1 (ja) 抗シナプトタグミン2抗体
WO2025084395A1 (ja) 抗シナプトタグミン2抗体
WO2025089342A1 (ja) 抗シナプス小胞糖タンパク質2c抗体
WO2025089341A1 (ja) 抗シナプス小胞糖タンパク質2c抗体
WO2025089344A1 (ja) 抗シナプス小胞糖タンパク質2c抗体
WO2025089343A1 (ja) 抗シナプス小胞糖タンパク質2c抗体
WO2025089346A1 (ja) 抗シナプトフィジン抗体
WO2025089345A1 (ja) 抗シナプトジャイリン3抗体
WO2025089349A1 (ja) 抗シナプトフィジン抗体
WO2025089347A1 (ja) 抗シナプトフィジン抗体
WO2025089348A1 (ja) 抗シナプトフィジン抗体
WO2023220639A2 (en) Methods and compositions for improved memory in the aging
CA3257052A1 (en) Targeting agent